| Heritage Hall King George | |
| 10051 Foxes Way, King George, Virginia 22485 | |
| (540) 775-4000 | |
| Name | Heritage Hall King George |
|---|---|
| Location | 10051 Foxes Way, King George, Virginia |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 130 |
| Occupancy Rate | 61% |
| Medicare ID (CCN) | 495300 |
| Legal Business Name | King George Life Care, Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1417449422 |
| Organization Name | KING GEORGE LIFE CARE, LLC |
| Doing Business As | HERITAGE HALL - KING GEORGE |
| Address | 10051 Foxes Way, King George, VA 22485 |
| Phone Number | 540-775-4000 |
News Archive
Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene.
The Pharmaceutical Benefits Advisory Committee has again recommended KALYDECO (ivacaftor) for listing on the Pharmaceutical Benefits Scheme (PBS). However, Vertex is deeply disappointed in the conditions the PBAC has attached to the recommendation. These conditions fail to reflect the substantial clinical benefits recognised by the PBAC, and would result in limiting the number of eligible Australians who would be able to receive KALYDECO.
Malaria is almost under control in Suriname. According to an impact study conducted by Hélène Hiwat - van Laar, who was awarded a PhD on the subject on 21 November at Wageningen University, a five-year control programme with new strategies has proved successful. The people most at risk nowadays are the mobile gold miner communities, especially those along the French Guianese border.
Three UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their investigations of treatment strategies for degenerative muscle diseases, such as muscular dystrophy, and heart disease, and to determine why human embryonic stem cells are susceptible to forming tumors.
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
› Verified 5 days ago
| NPI Number | 1780675702 |
| Organization Name | KING GEORGE LIFE CARE, LLC |
| Doing Business As | HERITAGE HALL - KING GEORGE |
| Address | 10051 Foxes Way, Box 495, King George, VA 22485 |
| Phone Number | 540-775-4000 |
News Archive
Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene.
The Pharmaceutical Benefits Advisory Committee has again recommended KALYDECO (ivacaftor) for listing on the Pharmaceutical Benefits Scheme (PBS). However, Vertex is deeply disappointed in the conditions the PBAC has attached to the recommendation. These conditions fail to reflect the substantial clinical benefits recognised by the PBAC, and would result in limiting the number of eligible Australians who would be able to receive KALYDECO.
Malaria is almost under control in Suriname. According to an impact study conducted by Hélène Hiwat - van Laar, who was awarded a PhD on the subject on 21 November at Wageningen University, a five-year control programme with new strategies has proved successful. The people most at risk nowadays are the mobile gold miner communities, especially those along the French Guianese border.
Three UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their investigations of treatment strategies for degenerative muscle diseases, such as muscular dystrophy, and heart disease, and to determine why human embryonic stem cells are susceptible to forming tumors.
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene.
The Pharmaceutical Benefits Advisory Committee has again recommended KALYDECO (ivacaftor) for listing on the Pharmaceutical Benefits Scheme (PBS). However, Vertex is deeply disappointed in the conditions the PBAC has attached to the recommendation. These conditions fail to reflect the substantial clinical benefits recognised by the PBAC, and would result in limiting the number of eligible Australians who would be able to receive KALYDECO.
Malaria is almost under control in Suriname. According to an impact study conducted by Hélène Hiwat - van Laar, who was awarded a PhD on the subject on 21 November at Wageningen University, a five-year control programme with new strategies has proved successful. The people most at risk nowadays are the mobile gold miner communities, especially those along the French Guianese border.
Three UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their investigations of treatment strategies for degenerative muscle diseases, such as muscular dystrophy, and heart disease, and to determine why human embryonic stem cells are susceptible to forming tumors.
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 15.08 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.79 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 59.13 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.48 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.43 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.3 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0.29 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.14 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 11.33 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 99.16 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.7 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 31.19 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 15.57 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.97 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.92 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 83.29 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 90.96 | 82.93 |
News Archive
Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene.
The Pharmaceutical Benefits Advisory Committee has again recommended KALYDECO (ivacaftor) for listing on the Pharmaceutical Benefits Scheme (PBS). However, Vertex is deeply disappointed in the conditions the PBAC has attached to the recommendation. These conditions fail to reflect the substantial clinical benefits recognised by the PBAC, and would result in limiting the number of eligible Australians who would be able to receive KALYDECO.
Malaria is almost under control in Suriname. According to an impact study conducted by Hélène Hiwat - van Laar, who was awarded a PhD on the subject on 21 November at Wageningen University, a five-year control programme with new strategies has proved successful. The people most at risk nowadays are the mobile gold miner communities, especially those along the French Guianese border.
Three UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their investigations of treatment strategies for degenerative muscle diseases, such as muscular dystrophy, and heart disease, and to determine why human embryonic stem cells are susceptible to forming tumors.
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
› Verified 5 days ago
Heritage Hall King George Location: 10051 Foxes Way, King George, Virginia 22485 Phone: (540) 775-4000 |